U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07146893) titled 'Feasibility Study for Repurposing RET Inhibitors' on Aug. 21.
Brief Summary: The purpose of this study is to assess the effects of selpercatinib on cachexia and anorexia in patients diagnosed with NSCLC, colorectal cancer, or pancreatic cancer.
Study Start Date: Nov. 30, 2025
Study Type: INTERVENTIONAL
Condition:
Cachexia-Anorexia Syndrome
Intervention:
DRUG: Selpercatinib
Patients will be instructed to take selpercatinib orally (PO) twice daily (BID), approximately every 12 hours. While on study, they will undergo weight measurements and regular blood draws every 4 weeks. At the 16-week post-treatment follow-up, patients wil...